Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
18F-FITM
- Development stage
- Preclinical
- Lead developer
- National Institute for Quantum Science and Technology
- Modality
- Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Positron Emitters → Radiopharmaceuticals, Small Molecules
- Administration
- Intravenous
01
Overview
18F-FITM (also known as [18F]FITM) is an experimental radiolabeled small molecule developed by the National Institute of Radiological Sciences (now part of the National Institutes for Quantum Science and Technology) in Japan. It acts as a highly selective positron emission tomography (PET) radioligand and negative allosteric modulator targeting the metabotropic glutamate receptor subtype 1 (mGluR1). 18F-FITM is designed for noninvasive PET imaging to map the distribution, density, and drug occupancy of mGluR1 in the brain, which is of interest for studying central nervous system disorders. Additionally, it has been investigated for the imaging and characterization of mGluR1 expression in melanoma and melanoma metastases.
- Other names
- 4-(18)F-fluoro-N-[4-[6-(isopropylamino)pyrimidin-4-yl]-1,3-thiazol-2-yl]-N-methylbenzamide4-[18F]fluoro-N-[4-[6-(isopropylamino)pyrimidin-4-yl]-1,3-thiazol-2-yl]-N-methylbenzamide[18F]FITM
02
Targets
GRM1 (Metabotropic glutamate receptor 1)
Beyond the preview
Go deeper on 18F-FITM.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on 18F-FITM.